MSD Collaborates with Novocure to Evaluate Tumor Treating Fields Together with Keytruda (pembrolizumab) in Non-Small Cell Lung Cancer

July 16, 2020 Auto Bot Collaborates, Evaluate, KEYTRUDA, Latest, MSD, Non-Small Cell Lung Cancer, pembrolizumab, Pharma 0

Shots:

  • The companies plan to conduct a P-II pilot study of tumor treating fields concomitant with Keytryda for 1L treatment of intrathoracic advanced/ metastatic PD-L1+ NSCLC. The study will enroll ~66 patients with its anticipated initiation in H2’20
  • The 1EPs od the study will be ORR while the 2EPs include OS, PFS, PFS@6mos., one-year survival rate, DoR, disease control rate @18wks. and safety
  • Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing cancer cells to die and causes minimal damage to healthy cell

Click here to read full press release/ article | Ref: PRNewswire | Image: MedPage Today